The COCOON trial reveals that prophylactic treatment reduces dermatological adverse events in NSCLC patients, enhancing their quality of life during amivantamab therapy.
Alexander I. Spira, MD, PhD
Advertisement
Articles by Alexander I. Spira, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
3
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
4
Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS
5